Presented By Michael Lee at 2016 ASCO Annual Meeting

Slides:

Advertisements

Similar presentations

TOP2A IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN UNSELECTED BREAST CANCER Amit Pancholi Molecular Profiling of Breast Cancer: Predictive Markers of Long.

Advertisements

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Triple-Negative Breast Cancer

Zeroing in on Non-Small Cell Lung Cancer: Integrating Targeted Therapies into Practice.

Immune therapy in NSCLC Presentation – 劉惠文 Supervisor – 劉俊煌教授.

Impact of the Type and Modalities of Preoperative Chemotherapy on the Outcome of Liver Resection for Colorectal Metastases R. Adam, E. Barroso, C. Laurent,

A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Inhibitor Gefitinb in Completely Resected Stage.

Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.

Hazard Ratio 0.62 ( ) P =.024 Larynx and Hypopharynx Overall Survival 166 Patients.

Kerrington Smith, M.D. CTOS Nov 14, 2008

Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

KRAS status and efficacy in the first- line treatment of patients with mCRC treated with FOLFOX with or without cetuximab: The OPUS experience Carsten.

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

IntroductionPatient baseline characteristics Conclusion The process of EGFR recycling is important mechanism of resistance of cetuximab in colorectal cancer.

Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer ? N. Perez-Staub, B. Chibaudel, A. Figer, A. Cervantes,

Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting.

Clinicopathologic Features of EML4-ALK Mutant Lung Cancer Shaw AT et al. ASCO 2009; Abstract (Poster)

Presented By Michael Overman at 2016 ASCO Annual Meeting

Dr. Marco Matos JOURNAL CLUB GCUH 4/07/14.

Presented By Shin Fujita at 2016 ASCO Annual Meeting

Presented By Alan Venook at 2016 ASCO Annual Meeting

miRNA-targets cross-talks: key players in glioblastoma multiforme

CCO Independent Conference Coverage

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Aspirin Associated With Reduced Mortality in Patients With CRC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 - June 2,

Prognostic Factors for First-line Chemotherapy + Bevacizumab or Cetuximab in Metastatic Colorectal Cancer CCO Independent Conference Highlights* of the.

Rosell R et al. Proc ASCO 2011;Abstract 7503.

Maintenance Lapatinib After Chemotherapy in HER1/2-Positive Metastatic Bladder Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma Zoltan Lohinai, MD, Mir Alireza Hoda, MD,

TBCRC (the translational breast cancer research consortium) 005 Prospective study

Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Presented By John Bartlett at 2017 ASCO Annual Meeting

Presented By Luca Malorni at 2017 ASCO Annual Meeting

CLINICAL AND BUDGET IMPACT OF USING A MOLECULAR TEST TO DETECT KRAS MUTATIONS IN METASTATIC COLORECTAL CANCER PATIENTS IN THE UNITED STATES Cheng I1, Hertz.

Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies A. Vogel, R.D. Hofheinz, S. Kubicka, D. Arnold

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.

BRAF mutant mCRC patients – What would you recommend? FOLFIRINOX/Bev

Unità Clinica di Diagnostica Istopatologica e Molecolare

New ESMO Guidance on Tumor Sidedness in mCRC

A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.

What to Do Next: Sequencing of Therapy in Patients With Metastatic CRC

Colorectal Cancer: Current “Standard” Uses for Molecular Testing

Genetic variants of kinases suppressors of Ras (KSR)in KRAS-BRAF

Volume 150, Issue 4, Pages (April 2016)

Presented By Johanna Bendell at 2016 ASCO Annual Meeting

Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011

A subgroup analysis of a large multicenter study

EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy Michele.

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.

Table 2. Progression-Free Survival

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma Zoltan Lohinai, MD, Mir Alireza Hoda, MD,

Targeting T Cell Co-receptors for Cancer Therapy

Kaplan–Meier survival curves of overall survival (OS) for EGFR mutant lung adenocarcinoma patients who received epidermal growth factor receptor tyrosine.

Published online September 20, 2017 by JAMA Surgery

Martin M et al. Proc SABCS 2012;Abstract S1-7.

Cetuximab with chemotherapy as 1st-line treatment for metastatic colorectal cancer: a meta-analysis of the CRYSTAL and OPUS studies according to KRAS.

KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: The.

Primary side of origin affects the outcome of mCRC patients treated with first-line FOLFIRI plus bevacizumab independently of BRAF status and mucinous.

(A) Survival time. (A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups.

Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non- small Cell Lung Cancer Patients Aged 70 Years or Older Yuh-Min Chen,

Ali Shamseddine,MD,FRCP

Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) for EGFR mutant lung adenocarcinoma.

Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi,

Fig. 1. Kaplan-Meier curves for PFS and OS

Overall Survival and Progression-free Survival

General strategies of Cancer Treatment and evaluation of Response

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Presentation transcript:

Presented By Michael Lee at 2016 ASCO Annual Meeting Association of primary site and molecular features with progression-free survival and overall survival of metastatic colorectal cancer after anti-epidermal growth factor receptor therapy Presented By Michael Lee at 2016 ASCO Annual Meeting

Presented By Michael Lee at 2016 ASCO Annual Meeting Learning Objectives Presented By Michael Lee at 2016 ASCO Annual Meeting

Presented By Michael Lee at 2016 ASCO Annual Meeting Background Presented By Michael Lee at 2016 ASCO Annual Meeting

Presented By Michael Lee at 2016 ASCO Annual Meeting Outline Presented By Michael Lee at 2016 ASCO Annual Meeting

Clinical study population and methods Presented By Michael Lee at 2016 ASCO Annual Meeting

Right-sided tumors are associated with inferior OS Presented By Michael Lee at 2016 ASCO Annual Meeting

Presented By Michael Lee at 2016 ASCO Annual Meeting Age, MSI, BRAF, and Methylation (CIMP) are associated with right-sided primaries Presented By Michael Lee at 2016 ASCO Annual Meeting

… and these associated factors are also prognostic Presented By Michael Lee at 2016 ASCO Annual Meeting

Side is not significant on multivariate analysis of OS Presented By Michael Lee at 2016 ASCO Annual Meeting

Presented By Michael Lee at 2016 ASCO Annual Meeting Right-sided primaries are more likely to have concomitant genetic features associated with poor outcomes Presented By Michael Lee at 2016 ASCO Annual Meeting

Presented By Michael Lee at 2016 ASCO Annual Meeting Outline Presented By Michael Lee at 2016 ASCO Annual Meeting

Which factors impact efficacy of anti-EGFR therapy? Presented By Michael Lee at 2016 ASCO Annual Meeting

Right-side is associated with inferior PFS with anti-EGFR therapy Presented By Michael Lee at 2016 ASCO Annual Meeting

Tumor biology associated with poor response to anti-EGFR therapy Presented By Michael Lee at 2016 ASCO Annual Meeting

Side is not significant on multivariate analysis of anti-EGFR PFS Presented By Michael Lee at 2016 ASCO Annual Meeting

Presented By Michael Lee at 2016 ASCO Annual Meeting Interim Conclusions Presented By Michael Lee at 2016 ASCO Annual Meeting

Presented By Michael Lee at 2016 ASCO Annual Meeting Outline Presented By Michael Lee at 2016 ASCO Annual Meeting

Gene expression study population Presented By Michael Lee at 2016 ASCO Annual Meeting

Established gene expression profiles Presented By Michael Lee at 2016 ASCO Annual Meeting

Right-sided primary is associated with CMS 1 & 3 Presented By Michael Lee at 2016 ASCO Annual Meeting

Low EREG/AREG expression in right-sided primaries Presented By Michael Lee at 2016 ASCO Annual Meeting

Presented By Michael Lee at 2016 ASCO Annual Meeting Conclusions Presented By Michael Lee at 2016 ASCO Annual Meeting

Presented By Michael Lee at 2016 ASCO Annual Meeting Acknowledgements Presented By Michael Lee at 2016 ASCO Annual Meeting